AIEQ · Exit · 1d
weight 1.730% → 0 (exited)·stock up 5.0% in the 30 days before
Aug 2·entry $118.43·now $120.16
+1.46%
since Aug 2
INCY
GrowthINCYTE CORPORATION.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Close · 3M
+26.67%
Held by 0 AI ETFs
None of the tracked AI ETFs currently hold this name.
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals4
Win rate100% (4/4)
Avg buy return+3.63%
AIEQ · Weight decrease · 2d
weight 1.820% → 1.730% (-0.090 pp)·stock up 5.0% in the 30 days before
Jul 31·entry $119.52·now $120.16
+0.54%
since Jul 31
AIEQ · Weight increase · 2d
weight 1.610% → 1.660% (+0.050 pp)·stock up 8.5% in the 30 days before
Jul 26·entry $118.87·now $120.16Fresh
+1.09%
since Jul 26
AIEQ · Weight increase · 2d
weight 1.580% → 1.630% (+0.050 pp)·stock up 17.5% in the 30 days before
Jul 19·entry $115.65·now $120.16Drifting
+3.90%
since Jul 19
AIEQ · Weight decrease · 2d
weight 1.610% → 1.580% (-0.030 pp)·stock up 6.0% in the 30 days before
Jul 15·entry $115.09·now $120.16
+4.41%
since Jul 15
AIEQ · Weight decrease · 2d
weight 1.650% → 1.610% (-0.040 pp)·stock up 13.1% in the 30 days before
Jul 11·entry $114.23·now $120.16
+5.19%
since Jul 11
AIEQ · Weight increase · 2d
weight 0 → 1.630% (new)·stock up 26.7% in the 30 days before
Jul 3·entry $115.62·now $120.16Drifting
+3.93%
since Jul 3
AIEQ · New entry · 1d
weight 0 → 1.560% (new)·stock up 19.1% in the 30 days before
Jul 1·entry $113.81·now $120.16Drifting
+5.58%
since Jul 1
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Too hard to callas of Jul 12
AI ETFs initially showed interest in Incyte, with AIEQ entering and increasing its weight, but then a recent weight decrease trend emerged. This shifting AI sentiment contrasts with the framework's 'Too Hard' verdict, which suggests avoiding the company altogether due to the fundamental unpredictability of its industry rather than reacting to short-term trends.
- Circle of CompetenceThe biotechnology industry's inherent unpredictability regarding drug discovery, regulatory approvals, and patent expirations makes long-term cash flow projections unreliable for this framework.
- Economic MoatA full assessment of an economic moat is not performed as the company fails the circle of competence stage.
- ManagementA full assessment of management is not performed as the company fails the circle of competence stage.
- Financial HealthA full assessment of financial health is not performed as the company fails the circle of competence stage.
- Margin of SafetyA full assessment of margin of safety is not performed as the company fails the circle of competence stage.
Incyte Corporation operates in the biotechnology sector, a domain characterized by high R&D risk, regulatory uncertainties, and patent cliffs that make long-term cash flow predictability extremely challenging. Within a Buffett-style framework, this business environment falls outside the circle of competence, making it impossible to reliably project future earning power. Therefore, the company is deemed 'Too Hard' to evaluate, regardless of its current financial performance or valuation metrics.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.